• 4459 Citations
  • 32 h-Index
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 0 Similar Profiles
Neoplasms Medicine & Life Sciences
LY-2157299 Medicine & Life Sciences
Pharmacokinetics Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Clinical Trials Medicine & Life Sciences
Phosphatidylinositol 3-Kinases Medicine & Life Sciences
Pharmaceutical Preparations Medicine & Life Sciences
Biomarkers Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2008 2019

Alpelisib Plus Fulvestrant in PIK3CA -Altered and PIK3CA -Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial

Juric, D., Janku, F., Rodon Ahnert, J., Burris, H. A., Mayer, I. A., Schuler, M., Seggewiss-Bernhardt, R., Gil-Martin, M., Middleton, M. R., Baselga, J., Bootle, D., Demanse, D., Blumenstein, L., Schumacher, K., Huang, A., Quadt, C. & Rugo, H. S., Feb 1 2019, In : JAMA Oncology. 5, 2

Research output: Contribution to journalArticle

Estrogen Receptors
Clinical Trials
Breast Neoplasms
Maximum Tolerated Dose
Phosphatidylinositol 3-Kinase

New clinical trial designs in the era of precision medicine

Garralda, E., Dienstmann, R., Piris-Giménez, A., Braña, I., Rodon Ahnert, J. & Tabernero, J., Mar 1 2019, In : Molecular oncology. 13, 3, p. 549-557 9 p.

Research output: Contribution to journalReview article

Open Access
Precision Medicine
Clinical Trials
Pharmaceutical Preparations
Drug Delivery Systems

Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules

Sankhala, K., Takimoto, C. H., Mita, A. C., Xiong, H., Rodon Ahnert, J., Mehrvarz Sarshekeh, A., Burns, K., Iizuka, K. & Kopetz, E. S., Feb 15 2019, In : Investigational New Drugs. 37, 1, p. 76-86 11 p.

Research output: Contribution to journalArticle

Appointments and Schedules
1 Citations (Scopus)

A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors

Rodon Ahnert, J., Curigliano, G., Delord, J. P., Harb, W., Azaro, A., Han, Y., Wilke, C., Donnet, V., Sellami, D. & Beck, T., Aug 1 2018, In : Oncotarget. 9, 60, p. 31709-31718 10 p.

Research output: Contribution to journalArticle

Phosphatidylinositol 3-Kinase
1 Citations (Scopus)

BRAF inhibition in BRAFV600-mutant gliomas: Results from the VE-BASKET study

Kaley, T., Touat, M., Subbiah, V., Hollebecque, A., Rodon Ahnert, J., Lockhart, A. C., Keedy, V., Bielle, F., Hofheinz, R. D., Joly, F., Blay, J. Y., Chau, I., Puzanov, I., Raje, N. S., Wolf, J., DeAngelis, L. M., Makrutzki, M., Riehl, T., Pitcher, B., Baselga, J. & 1 othersHyman, D. M., Dec 10 2018, In : Journal of Clinical Oncology. 36, 35, p. 3477-3484 8 p.

Research output: Contribution to journalArticle

Disease-Free Survival